- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05741242
Basket Trial de vacunas de péptido largo sintético de neoantígeno en pacientes con neoplasia maligna avanzada
A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a Simon-two stage multi-cohort study to assess the safety and efficacy of neoantigen synthetic long peptide vaccines in patients with local or metastatic solid tumors.
- To assess the efficacy of NeoSLP vaccination by investigator assessment of Progression-Free Survival at 12 months (PFS12).
- To assess efficacy of NeoSLP vaccination by assessment of Time to Treatment Failure (TTF).
- To assess efficacy of NeoSLP vaccination by assessment of Overall Survival at 24 months (OS24).
- To investigate the immunogenicity of NeoSLP vaccines by ELISpot assay. 5. To assess the safety and tolerability of NeoSLP vaccines.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
Beverly Hills, California, Estados Unidos, 90212
- Precision NextGen Oncology & Research Center
-
San Francisco, California, Estados Unidos, 94115
- Quest Clinical Research
-
Santa Monica, California, Estados Unidos, 90403
- Asthra Health
-
-
Florida
-
Miami Beach, Florida, Estados Unidos, 33140
- Mount Sinai Comprehensive Cancer Center
-
-
Missouri
-
Bridgeton, Missouri, Estados Unidos, 63044
- St. Louis Cancer Care
-
-
New York
-
New York, New York, Estados Unidos, 10028
- Anna Gattani MD PC
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Patients must satisfy the following criteria to be enrolled in the protocol:
Main Inclusion Criterion:
Pancreatic
- Patients who have local or metastatic pancreatic adenocarcinoma and have started first line therapy of Folfirinox (physician's choice for any concomitant therapies)
- Patients who have undergone somatic tumor sequencing should consider FDA-approved pan-solid tumor therapies if they harbor an FDA-approved somatic alteration. For example, Entrectinib or Larotrectinib (if NTRK gene fusion- positive), Selpercatinib (if RET gene fusion-positive), Pembrolizumab (if MSI-H, dMMR, or TMB-H[≥10 mut/Mb]), and PARP inhibitors (BRCA mutations).
Glioblastoma
1. Patients who are within 6 months of diagnosis and have detectable disease as determined by investigator assessment at the start of vaccine administration.
Basket
1. Patients with local or metastatic malignancies, limited treatment options, and an estimated 5-year survival of less than 50% are eligible for enrollment in this cohort.
Other Inclusion Criteria:
- >= 12 years of age.
- ECOG performance status ≤ 2 or Karnofsky score of >=70.
- Adequate organ function allowing favorable benefit to risk ratio per the treating physician
- Systemic corticosteroid therapy is permitted provided dosing is no greater than 4 mg per day (dexamethasone or equivalent) on the day of vaccine administration.
- Ability to understand and willingness to sign an IRB approved written informed consent document.
Exclusion Criteria:
- History of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty or known allergy to a component of the neoantigen synthetic long peptide vaccine.
- Intercurrent illness requiring chronic use of medications that may interfere with rescue medications for treatment of vaccine-related anaphylaxis or attenuate immune response to vaccine treatment (immunosuppressive therapies).
- Psychiatric illness or social situations that would limit compliance with study requirements.
- History of pre-existing immunodeficiency disorder or autoimmune condition requiring immunosuppressive therapy that would preclude response to vaccine.
- Females of childbearing potential may participate provided they agree to practice abstinence; and, if heterosexually active, agree to use at least 2 highly effective contraceptive methods throughout the study and for 3 months following the last dose of study drug; and have a negative serum pregnancy test.
- Females of non-childbearing potential must be post-menopausal or have been surgically sterilized.
- Male subjects with a female partner of childbearing potential must agree to practice abstinence or to use a physician-approved contraceptive method throughout the study and for 3 months following the last dose of study drug.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Vacuna personalizada de péptido largo sintético
|
Personalized Synthetic Long Peptide Vaccine |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
To assess the efficacy of NeoSLP vaccination by investigator assessment of Progression-Free Survival at 12 months (PFS12).
Periodo de tiempo: Until progression or death, assessed up to 12 months post first vaccine administration.
|
Progression-Free Survival at 12 months (PFS12) defined as time from first vaccine administration until disease progression by investigator assessment or death due to any cause. |
Until progression or death, assessed up to 12 months post first vaccine administration.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
To assess efficacy of NeoSLP vaccination by assessment of Time to Treatment Failure (TTF).
Periodo de tiempo: Assessed up to 12 months post first vaccine administration
|
Time to Treatment Failure (TTF) is defined as time from first vaccine administration to discontinuation of treatment due to any reason, including disease progression, treatment toxicity, and death. |
Assessed up to 12 months post first vaccine administration
|
|
To assess efficacy of NeoSLP vaccination by assessment of Overall Survival at 24 months (OS24).
Periodo de tiempo: Until death, assessed up to 24 months post first vaccine administration
|
Overall Survival at 24 months (OS24) is the landmark of OS defined as the proportion of patients alive at 24 months. |
Until death, assessed up to 24 months post first vaccine administration
|
|
To assess the safety and tolerability of NeoSLP vaccines.
Periodo de tiempo: Assessed up to 60 days from last vaccine administration
|
Adverse Events (AEs) and Severe Adverse Events (SAEs) |
Assessed up to 60 days from last vaccine administration
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
To investigate the immunogenicity of NeoSLP vaccines by ELISpot assay.
Periodo de tiempo: Assessed at baseline before first vaccine administration and day 50 post
|
Immune monitoring is defined as the percentage of patients showing an immune response to the vaccine components. |
Assessed at baseline before first vaccine administration and day 50 post
|
Colaboradores e Investigadores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- JLF-200
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .